Multiple sclerosis: trial of a synthetic polypeptide

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Clinical Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Experimental Allergic Encephalomyelitis (EAE) is a model for MS, often suppressed by Copolymer I (COP I).
• COP I is a synthetic polypeptide composed of alanine, glutamic acid, lysine, and tyrosine.

Purpose of the Study:

• To evaluate the safety and efficacy of COP I in patients with multiple sclerosis.
• To assess the potential of COP I to alter the disease course in chronic progressive and exacerbating-remitting MS.

Main Methods:

• A preliminary open-label trial involving 16 patients with multiple sclerosis (12 chronic progressive, 4 exacerbating-remitting).
• Patients received COP I therapy for up to two years.
• Adverse events and clinical outcomes were monitored.

Main Results:

• COP I was well-tolerated, with no undesirable side reactions reported in any patient.
• A subset of patients showed improvement: 3 with chronic progressive MS and 2 with exacerbating-remitting MS.
• The observed improvements require further validation due to potential placebo effects.

Conclusions:

• COP I demonstrates a favorable safety profile in MS patients.
• Preliminary findings suggest potential therapeutic benefits of COP I for multiple sclerosis.
• Randomized, placebo-controlled trials are underway to confirm these initial results.